FC
JAZZ icon

Farringdon Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Farringdon Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Buy
+1,092
New +$191K 0.05% 344
2025
Q3 		– Sell
-3,502
Closed -$372K – 560
2025
Q2 		$372K Sell
3,502
-2,788
-44% -$303K 0.12% 276
2025
Q1 		$781K Buy
+6,290
New +$821K 0.39% 55

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Farringdon Capital's JAZZ Position: Q1 2026 in Review

Farringdon Capital opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 1,092 shares worth $206K. The stake represents 0.05% of the portfolio and ranks #344 among its holdings. This is a return to the name: Farringdon Capital previously reported a position in JAZZ as recently as Q2 2025.

Farringdon Capital first reported a position in JAZZ in Q1 2025 and has held it in 3 quarters since. The position peaked at $781K in Q1 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Farringdon Capital held 1,092 shares of Jazz Pharmaceuticals worth $206K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Farringdon Capital position in Q1 2026.
  • Jazz Pharmaceuticals made up 0.05% of Farringdon Capital's portfolio in Q1 2026, its #344 holding.
  • Farringdon Capital first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Farringdon Capital's Jazz Pharmaceuticals position peaked at $781K in Q1 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Farringdon Capital's 13F filing for Q1 2026, filed 15 May 2026.